Munich, 25 October 2024 - The Management Board of Ringmetall SE (ISIN: DE000A3E5E55) today reached an agreement on the acquisition of Peak Packaging Poland Sp. z o.o. by way of a share deal with ...
Laxxon Medical Corp., a leading pharma technology company in oral drug delivery, today announced that the Company will host a fireside chat at the UBS Global Healthcare Conference on Thursday, ...
Schramberg, 25 October 2024 - Based on the most recent order indications and expectations for the business development, the Management Board of hGears AG has adjusted its full year 2024 guidance.
HelloFresh SE expects adjusted EBITDA (“AEBITDA”) for Q3 2024 meaningfully above market expectations, reduces its revenue growth outlook and raises the lower end of its AEBITDA outlook for the fiscal ...
Nordwest Industrie Finance GmbH successfully places Nordic Bond in the volume of EUR 50 million ...
Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 24.10.2024 / 18:56 CET/CEST Dissemination of a Voting Rights ...
The Executive Board of IVU Traffic Technologies AG today approved a buyback programme for its own shares. The resolution is based on the authorisation granted by the Annual General Meeting on 29 May ...
«We are delighted with the overwhelming support and the clear signal from the bondholders. This is an extremely strong signal to the GZO leaders and the administrators that the creditors' consent is ...
Person subject to the notification obligation is not controlled nor does it control any other undertaking (s) that directly or indirectly hold (s) an interest in the (underlying) issuer (1.).
GENEVA (OCT. 25, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for ...
Based on preliminary and unaudited figures, Hapag-Lloyd AG achieved a Group EBITDA of approximately USD 3.6 billion (EUR 3.3 billion) and Group EBIT of approximately USD 1.9 billion (EUR 1.8 billion) ...
Zentiva and Paragon, the main shareholder of APONTIS PHARMA, have entered into a share sale and purchase agreement with respect to its stake of approx. 37.5% of APONTIS PHARMA shares at a cash ...